Skip to main content
. 2016 May 17;38(13):961–969. doi: 10.1093/eurheartj/ehw203

Figure 2.

Figure 2

Time-to-event curves for the primary efficacy and safety endpoints *primary efficacy endpoint (clinically driven target-lesion revascularization) **primary safety endpoint (cardiac death, myocardial infarction, or definite and probable stent thrombosis).